You are here

Juxtapid

New CEO Szela cuts Aegerion staff again, pulls Juxtapid out of the EU

Endpoints

Thu, 07/21/16 - 09:14 am

Aegerion Pharmaceuticals

Aegerion to plead guilty to misbranding cholesterol drug, will pay $40 million

BioPharma Dive

Fri, 05/13/16 - 10:17 am

Aegerion's Rare Disease Drug Launch Stalls

TheStreet.com

Wed, 05/7/14 - 08:58 am

Companies Betting on the Next 10 Blockbuster Drugs

24/7WallStreet

Wed, 04/23/14 - 11:57 am

Intercept Pharma

Ironwood Pharmaceuticals

H.P. Acthar Gel

Questcor Pharmaceuticals

Sarepta Therapeutics

Aegerion gets DOJ subpeona over marketing of cholesterol drug Juxtapid

Yahoo/Reuters

Fri, 01/10/14 - 08:23 am

Aegerion reports results from Phase 3 study of Juxtapid

Yahoo/Fly on the Wall

Tue, 11/19/13 - 07:27 am

Homozygous Familial Hypercholesterolemia

Why Aegerion Is Worth 1,732 Times Sales

Seeking Alpha

Wed, 06/12/13 - 08:50 am

Aegerion Continues To Gain Momentum As Analysts Raise Price Targets

Seeking Alpha

Thu, 05/30/13 - 04:49 pm

2 Orphan Drugmakers With Upcoming Catalysts

Seeking Alpha

Wed, 04/24/13 - 04:46 pm

Raptor Pharmaceuticals

Better Than Lipitor! Higher Sales?

Motley Fool

Tue, 01/1/13 - 11:53 am

Isis Pharmaceuticals

PCSK9 inhibitors

Aegerion says FDA approves Juxtapid, a treatment for a rare high cholesterol disorder

Yahoo/AP

Mon, 12/24/12 - 10:30 am

Homozygous Familial Hypercholesterolemia